Business Context and Reporting Period
This Form 8-K filing by Artelo Biosciences, Inc. (Nasdaq: ARTL) reports on events occurring between September 4, 2025, and September 11, 2025. The report details the partial exercise of an over-allotment option related to a previously announced underwritten public offering.
Key Financial Metrics
The filing focuses on capital raising activities rather than operational performance metrics such as revenue or profit.
- Gross Proceeds from Over-allotment: Approximately $0.25 million.
- Net Proceeds from Over-allotment: Approximately $0.24 million.
- Shares Issued in Over-allotment: 57,914 shares of Common Stock.
- Price per Share: $4.40 (consistent with the initial offering price).
- Initial Offering Context: The primary offering closed on September 5, 2025, generating approximately $3.0 million in gross proceeds from 640,924 shares and 40,894 pre-funded warrants.
Material Changes
The material change reported is the increase in share count and capital raised due to the Underwriter's partial exercise of the 45-day over-allotment option on September 11, 2025. The Underwriter purchased 57,914 of the 102,272 shares available under the option.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks beyond the standard disclosure of the transaction terms. The transaction was executed with R. F. Lafferty & Co., Inc. as the sole book-running manager.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction (initial 640,924 shares + 57,914 over-allotment shares + 40,894 pre-funded warrants).
- Confirm the exact underwriting discounts and commissions deducted to arrive at the $0.24 million net proceeds.
- Review the remaining unexercised portion of the over-allotment option (44,358 shares) and its expiration date (45 days from September 4, 2025).
- Check subsequent filings for the use of proceeds from the aggregate offering.